The One Click Group

The One Click Group
Health Advocacy

RSS Feed Follow OneClickGroup on Twitter

Dr Iain Stephenson
Found Guilty of Vaccine
Research Fraud
The One Click Group

Mobilising ME/CFS Charities
To Smash Flawed
PACE Trial Results
Lara, Health Advocate

UK Public Health
In Dire Straits
Dr Dick van Steenis MBBS

Lies Damned Lies
Swine Flu
Statistics Exposed
By Lara

Vaccination Graphs
The Awful Stats In Action
Raymond Obomsawin Ph.D

Issues In Immunization
Theory And Practice
Raymond Obomsawin Ph.D

March 2010

One Click
Of Information
UK Police Harassment
In The Internet Era

Barbara Loe Fisher
NVIC Conference
Style, Gonads
Brass Ovaries
By Jane Bryant

New Journalism
Status Quo
By Jane Bryant
NVIC Conference

How The
Judicial Review
NICE Guidelines
Was Lost
Jane Bryant
The One Click Group

Vaccines Propaganda
David Salisbury
Public Relations

David Southall
"A Very
Dangerous Doctor"
Panorama swims
with sharks
Lisa Blakemore Brown

Dr David Salisbury
Never Mind Me,
I'm Basil Fawlty!

David Salisbury
Vaccine Litigation

The Politics
And Commerce
Of Autism
By Lisa Blakemore Brown

Vaccine/Autism Case
Mitochondrial Disfunction
ME/CFS Patients

The Consensus Report
Family Law Reform

Canadian Definition of ME-CFS

The Weird World of Wikipedia
By Martin J. Walker

Click here to email us with any thoughts or opinions you wish to share about the website.


News Archives 3841-3860
Number Title Post Date
3841 Drug Dealer Bayer Paying Over $60 Million To Settle Deadly Trasylol Drug Suits 18/08/2010 11:28:11
3842 Outrage As Disgraced CPS Refuses To Charge Killer Doctor Jane Barton 18/08/2010 11:31:12
3843 Barack Obama Sharply Embarrassed By WikiLeaks 18/08/2010 11:35:27
3844 Draconian Thai Government Blocks Access To WikiLeaks Website 18/08/2010 11:41:15
3845 Vaccine Ingredient Calculator Updated! 19/08/2010 13:49:32
3846 GSK's Swine Flu Vaccine Suspected Of Causing Narcolepsy In Children 19/08/2010 13:53:12
3847 Iceland Set To Be Global Press Freedom Haven 19/08/2010 13:55:09
3848 Resurrecting WikiLeaks In Thailand 19/08/2010 13:57:57
3849 WikiLeaks Wins Credibility War 19/08/2010 14:06:17
3850 Judge Attacks Social Services For Trying To FORCE Contraception On Low IQ Woman 20/08/2010 13:24:17
3851 Vaccination Against HPV Is Dangerous And Unnecessary 20/08/2010 13:28:49
3852 GlaxoSmithKline Use Irish Children As Guinea Pigs In Vaccine Trials Scandal 20/08/2010 13:31:13
3853 Drug Dealer GlaxoSmithKline Memo On Deadly Avandia Is Questioned 20/08/2010 13:34:48
3854 Antiwar Activists Rally To Support Suspected Leaker Bradley Manning 20/08/2010 13:36:44
3855 WikiLeaks Encryption Makes For Interesting Legal Question 20/08/2010 13:40:12
3856 Swedish Rape Warrant For WikiLeaks' Julian Assange Cancelled 21/08/2010 16:28:03
3857 Five Shamed MPs Fail To Repay 40k Expenses 22/08/2010 11:43:10
3858 Files Go Missing In Ireland's Child Vaccine Scandal 22/08/2010 12:00:40
3859 Four Babies Killed By Measles Vaccine 22/08/2010 12:02:13
3860 GMC Issues Details Of Entirely Flawed Child Protection Consultation 22/08/2010 12:04:09

[Previous] [Next]

Drug Dealer GlaxoSmithKline Memo On Deadly Avandia Is Questioned
Share |

Glaxo Memo on Avandia Is Questioned

August 19, 2010

Dr. David Graham, of the Food and Drug Administration, called Glaxo's summary “biased, misleading and not truthful.”

Federal drug regulators ordered GlaxoSmithKline to send a letter to crucial doctors describing a hearing in July where an expert advisory panel discussed the risks of Avandia, the company’s controversial diabetes medicine.

But a federal official and some members of the panel now say the company’s letter is misleading and could endanger patients. The dispute is occurring just weeks before the Food and Drug Administration is expected to announce whether Avandia’s label must include new warnings, whether sales of the drug will be restricted or whether Avandia must be withdrawn from the market.

Doctors who received the letter, dated July 28, are investigators in a study called the Tide trial, which was intended to compare the heart risks of Avandia with those of Actos, a similar drug made by Takeda Pharmaceuticals.

Results of the trial, which was requested by the F.D.A., are not expected for years. The ethics of the Tide trial were a point of contention at the advisory committee hearing, and the F.D.A. ordered GlaxoSmithKline to stop recruiting new patients into the trial, although current patients could continue.

Dr. David Graham, an F.D.A. medical officer, made an impassioned presentation at the advisory hearing arguing that the study should be stopped because thousands of patients in the trial were being exploited. None of these arguments were mentioned in GlaxoSmithKline’s letter.

“This summary is biased, misleading and not truthful,” Dr. Graham said in an interview. “The whole purpose of this letter is so that they can reassess whether this is an ethical trial going forward, but the step-by-step ethical flaws and problems with the Tide trial are not even referenced.”

Several members of the advisory committee complained that the company’s letter was biased.

“This letter is really deceptive,” said Dr. Clifford J. Rosen, a panel member. He added that the letter also did not refer to a presentation at the hearing by members of an Institute of Medicine study panel that said observational studies could be useful.

Dr. Curt D. Furberg, also a panel member, described the letter as a “very Avandia friendly” document that ignored much of the discussion criticizing the validity of GlaxoSmithKline’s studies. Other panel members expressed similar reservations.

But another panel member, Dr. Sanjay Kaul, disagreed, saying the letter “faithfully reflects the deliberations of the Avandia advisory meeting.”

Erica Jefferson, an F.D.A. spokeswoman, said that after ordering GlaxoSmithKline to send a summary of the hearing to the Tide trial investigators, the agency had relied on the company to provide a balanced account. “F.D.A. did not preclear or approve the content,” she said.

Mary Anne Rhyne, a GlaxoSmithKline spokeswoman, said the company had only one week to write the 10-page summary, which was necessarily brief. But the company and the leader of the Tide trial agreed that the letter “reflected the science and data discussed at the advisory committee meeting,” Ms. Rhyne said.

Dr. Steven Nissen, a Cleveland Clinic cardiologist who made a presentation before the committee arguing for Avandia’s withdrawal, said that GlaxoSmithKline’s letter did not mention that the committee had concluded that Avandia carried a higher risk of heart attack than Actos.

“Since the Tide trial compares these two alternative therapies, this omission does not meet any reasonable ethical standards,” Dr. Nissen said.

The dispute is part of a continuing battle over what the 33-member committee actually decided in July. The committee’s most important vote was on whether Avandia should remain on the market and, if so, how.

Five options were offered. No panel members voted for continuing the marketing of the drug and removing from the label the boxed warning and other warnings involving increased risk of stroke or heart attack.

Three panel members voted for no change; seven voted to add more warnings to the drug’s label; 10 voted to severely restrict the drug’s marketing; and 12 voted that the drug should be withdrawn. One abstained.

Some commentators emphasized that a majority of the panel had voted to keep the drug on the market. Others said that a majority had voted to withdraw or severely restrict the drug’s sales. The former group interpreted the meeting as largely positive for GlaxoSmithKline; the latter said it had been a blow to the company, which is based in Brentford, England.

If the drug is withdrawn, this latest dispute will disappear because the Tide trial itself will most likely end.

The F.D.A. usually follows the advice of its advisory committees, but not always.

Related Links:
* After Avandia: Does The FDA Have A Drug Problem?
Massimo Calabresi with Alice Park, TIME Magazine

UK Web Hosting by Fri, August 20th, 2010. 01:34 pm